Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL747 Safety and PK/PD in Alzheimer's Disease
NCT03757325Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Feb 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of DNL747 in Alzheimer's disease (AD) (2 arms), sponsored by Denali Therapeutics Inc. Primary endpoints: Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 86, Number of Subjects with clinically significant neurological examination abnormalities at Day 86 and 1 more. Started Feb 2019; status: completed.
02
Drugs
DNL747
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03757325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757325.